chufangao/CTO huggingface dataset:
Clinical trial NCT03018223: Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Official title: A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-01-31
Primary completion date: 2018-12-15
Completion date: 2021-03-18
Baseline population: All participants
Clinical trial NCT04177108: A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Official title: A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 242.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-11-25
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Baseline population: Intent-to-treat (ITT) population included all participants randomized in this study.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT06161792: Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer
Official title: A Randomized, Placebo-Controlled, Double-Blind, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of RCN3028 in Treatment of Drug-Induced Moderate to Severe Vasomotor Symptoms in Breast Cancer Subjects
Acronym: VMS
Sponsor: Yung Shin Pharm. Ind. Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty in recruiting breast cancer patients, leading to a slow rate of case enrollment.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-07
Primary completion date: 2022-03-14
Completion date: 2022-04-20
Plan to share individual participant data: NO
Clinical trial NCT03992326: Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Official title: Phase Ib Study To Assess The Feasibility And Safety Of Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes In Advanced Solid Tumors
Sponsor: Centre Hospitalier Universitaire Vaudois (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Internal competitive study that is open
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-01
Primary completion date: 2021-03-05
Completion date: 2021-03-05
Clinical trial NCT04217317: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Official title: Pilot Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accruals
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-16
Primary completion date: 2023-04-21
Completion date: 2024-07-11
Plan to share individual participant data: NO
Clinical trial NCT03987919: A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Official title: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Acronym: SURPASS-2
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1879.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-07-30
Primary completion date: 2021-01-28
Completion date: 2021-02-15
Baseline population: All randomized participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT05049161: A Long-term Extension of Study GNC-401
Official title: A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With Rituximab
Sponsor: GeNeuro SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Drug product unavailability
Enrollment: 33.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-27
Primary completion date: 2022-05-18
Completion date: 2022-05-18
Clinical trial NCT03545191: Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder
Official title: Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 930.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-04
Primary completion date: 2020-01-25
Completion date: 2020-02-25
Plan to share individual participant data: NO
Clinical trial NCT01937247: Redesigned Process in the Operating Room
Official title: Redesigned Process in the Operating Room: Monitoring and Evaluating Success of Reducing Non Operative Time
Sponsor: American University of Beirut Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-18
Primary completion date: 2020-10-30
Completion date: 2020-10-30
Plan to share individual participant data: NO
Clinical trial NCT05661669: Ketamine for the Treatment for Alcohol Use Disorder in the ED
Official title: Ketamine for the Treatment for Alcohol Use Disorder in the Emergency Department: A Pilot Double-blind, Placebo-controlled Randomized Clinical Trial
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: After months of screening, we screened 175 individuals, only 3 were eligible, 2 declined, and 1 was moved to a different floor before study activities were able to take place.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-25
Primary completion date: 2024-06-06
Completion date: 2024-06-06
Clinical trial NCT03594747: A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
Official title: A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 360.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-30
Primary completion date: 2020-09-30
Completion date: 2023-04-28
Baseline population: Intent-to-treat (ITT) analysis set included all participants who were randomized. Data are presented as of the study completion data cut-off date of 28APR2023.
Plan to share individual participant data: YES
Clinical trial NCT04473716: Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Official title: Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial
Sponsor: Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-30
Primary completion date: 2021-04-12
Completion date: 2023-09-30
Clinical trial NCT04853134: Proxalutamide Treatment for COVID-19 Female Outpatients
Official title: Proxalutamide Treatment for COVID-19 Female Outpatients
Sponsor: Applied Biology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: This study was combined with another study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-01
Primary completion date: 2021-12-01
Completion date: 2021-12-01
Clinical trial NCT04395716: A Study of ResCure™ to Treat COVID-19 Infection
Official title: A Phase I Study of ResCure™ to Treat COVID-19 Infection
Sponsor: ProgenaBiome (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Not ever started
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-31
Primary completion date: 2021-06-30
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT02872519: PET Imaging of Ovarian Carcinoma With 18F-FSPG
Official title: PET Imaging of Ovarian Carcinoma With 18F-FSPG
Sponsor: Vanderbilt-Ingram Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-30
Primary completion date: 2019-08-31
Completion date: 2020-08-31
Clinical trial NCT05002114: Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.
Official title: Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.
Acronym: CBD001
Sponsor: Louisiana State University Health Sciences Center Shreveport (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: there were issues with the primary study material that prohibited continuation at this time
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-31
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Plan to share individual participant data: NO
Clinical trial NCT04353817: A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
Official title: A Phase 3b, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 6 Through 11 Years of Age Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-19
Primary completion date: 2021-05-17
Completion date: 2021-05-17
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT04722601: A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
Official title: A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: funding
Enrollment: 2.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-09-01
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Clinical trial NCT04173338: Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Official title: Phase I Study of Cabozantinib in Combination With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC), Urothelial Cancer and Advanced Malignant Mesothelioma
Sponsor: Augusta University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Closed by IRB on 3/28/22
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-23
Primary completion date: 2022-03-28
Completion date: 2022-03-28
Clinical trial NCT03087201: CANNAbinoids in the Treatment of TICS (CANNA-TICS)
Official title: A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders
Acronym: CANNA-TICS
Sponsor: Hannover Medical School (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 98.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-05
Primary completion date: 2020-11-20
Completion date: 2020-11-20
Plan to share individual participant data: NO
Clinical trial NCT04339426: Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
Official title: Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection
Sponsor: HonorHealth Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Closed due to poor enrollment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-20
Primary completion date: 2022-02-11
Completion date: 2022-02-11
Plan to share individual participant data: NO
Clinical trial NCT05069012: Intrathecal Morphine for Cesarean Delivery
Official title: Optimal Dose of Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 72.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-15
Primary completion date: 2022-07-23
Completion date: 2022-07-23
Plan to share individual participant data: NO
Clinical trial NCT03819231: Mindfulness Training Plus Oxytocin Effects on Smoking Behavior
Official title: Mindfulness Training Plus Oxytocin to Reduce Smoking and Craving Among Smokers in Withdrawal
Acronym: MOXY
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Study completed early due to COVID-19 pandemic regulations.
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-10
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT04932941: MP1032 Treatment in Patients With Moderate to Severe COVID-19
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
Sponsor: MetrioPharm AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 132.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-19
Primary completion date: 2022-07-28
Completion date: 2022-09-05
Baseline population: The ITT Set corresponded with the randomized set and included all randomized participants, irrespective of any deviation from the protocol or premature discontinuation from the study drug or withdrawal from study.
Plan to share individual participant data: NO
Clinical trial NCT03827850: FGFR Inhibitor in FGFR Dysregulated Cancer
Official title: A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.
Acronym: FIND
Sponsor: Lung Cancer Group Cologne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study-related difficulties faced with patient enrolment, no safety-related reasons
Enrollment: 22.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-25
Primary completion date: 2022-09-30
Completion date: 2022-10-14
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02037529: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Official title: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Sponsor: Academic and Community Cancer Research United (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Total enrollment number is being lowered
Enrollment: 201.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-01-17
Primary completion date: 2021-02-11
Completion date: 2024-10-31
Baseline population: All enrolled patients
Clinical trial NCT05705167: Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care
Official title: A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital Care
Acronym: NEREIDA
Sponsor: PharmaMar (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Significant difficulties in the recruitment of patients
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-04-19
Primary completion date: 2024-03-19
Completion date: 2024-04-19
Clinical trial NCT02104817: Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Official title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)
Acronym: STRENGTH
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 13078.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-10-30
Primary completion date: 2020-05-27
Completion date: 2020-05-27
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03599622: An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Crohn's Disease
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Trial terminated because of lack of efficacy in the short term acute phase
Enrollment: 239.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-16
Primary completion date: 2022-12-12
Completion date: 2023-10-23
Limitations and caveats: Trial terminated because of lack of efficacy in the short term acute phase.
Clinical trial NCT03396874: Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Official title: Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1435.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-09
Primary completion date: 2022-08-09
Completion date: 2022-08-09
Limitations and caveats: For Outcome Measure 5, a quality check was performed of the results by analyzing electronic medical records. The analysis showed the questionnaire responses about treatment plans collected post-scan did not align with the actual treatments listed in the medical records.
Plan to share individual participant data: YES
IPD sharing description: Codified data will be archived and stored in an imaging repository with limited metadata for analysis. Individuals seeking use of these data should contact the study chair. A data sharing contract for a HIPAA limited dataset will need to be executed prior to data sharing.
IPD time frame: Available as requested. Data will be archived indefinitely for research purposes.
IPD access criteria: Individuals seeking use of these data should contact the study chair.
Clinical trial NCT04322396: Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
Official title: Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19
Acronym: ProPAC-COVID
Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recommended by the DSMB
Enrollment: 117.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-06
Primary completion date: 2021-02-02
Completion date: 2021-02-02
Limitations and caveats: Early termination based on recommendations from the DSMB leading to small numbers of subjects analyzed.
Clinical trial NCT03832738: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)
Acronym: IMPACT-PS
Sponsor: Akros Pharma Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 152.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-01-17
Primary completion date: 2020-03-13
Completion date: 2020-03-13
Baseline population: Baseline characteristics results are reported for the Intent-to-Treat (ITT) population: 152 randomized subjects
Plan to share individual participant data: NO
Clinical trial NCT02825576: Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine
Official title: Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine
Acronym: P-PERSON
Sponsor: Northern Sydney Anaesthesia Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of Study Personnel
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-03
Primary completion date: 2020-04-01
Completion date: 2021-01-01
Plan to share individual participant data: YES